These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 10097957)

  • 1. [Severe course of a mutilating pansclerotic circumscribed scleroderma in childhood. Clinical aspects and therapy].
    Stücker M; Schreiber D; Gruss C; Freitag M; von Kobyletzki G; Kerscher M; Altmeyer P
    Hautarzt; 1999 Feb; 50(2):131-5. PubMed ID: 10097957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disabling pansclerotic morphea of childhood--unusual case and management challenges.
    Forsea AM; Cretu AN; Ionescu R; Giurcaneanu C
    J Med Life; 2008; 1(3):348-54. PubMed ID: 20108512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultraviolet A1 phototherapy for the treatment of localized scleroderma.
    Furuhashi T; Torii K; Ikumi K; Kato H; Nishida E; Morita A
    J Dermatol; 2020 Jul; 47(7):792-795. PubMed ID: 32383187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disabling pansclerotic morphoea of childhood.
    Jamalpur I; Mogili HR; Koratala A
    BMJ Case Rep; 2018 Feb; 2018():. PubMed ID: 29455178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges in the diagnosis and treatment of disabling pansclerotic morphea of childhood: case-based review.
    Soh HJ; Samuel C; Heaton V; Renton WD; Cox A; Munro J
    Rheumatol Int; 2019 May; 39(5):933-941. PubMed ID: 30838436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphea and Eosinophilic Fasciitis: An Update.
    Mertens JS; Seyger MMB; Thurlings RM; Radstake TRDJ; de Jong EMGJ
    Am J Clin Dermatol; 2017 Aug; 18(4):491-512. PubMed ID: 28303481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disabling pansclerotic morphea of children.
    Diaz-Perez JL; Connolly SM; Winkelmann RK
    Arch Dermatol; 1980 Feb; 116(2):169-73. PubMed ID: 7356347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low dose UVA1 phototherapy in disabling pansclerotic morphoea of childhood.
    Gruss C; Stücker M; Kobyletzki G; Schreiber D; Altmeyer P; Kerscher M
    Br J Dermatol; 1997 Feb; 136(2):293-4. PubMed ID: 9068760
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of bosentan in treatment of unresponsive cutaneous ulceration in disabling pansclerotic morphea in children.
    Roldan R; Morote G; Castro Mdel C; Miranda MD; Moreno JC; Collantes E
    J Rheumatol; 2006 Dec; 33(12):2538-40. PubMed ID: 17143989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pansclerotic morphea with a rapidly fatal outcome in an 11-year-old girl].
    Hardy J; Audouin-Pajot C; Abid A; Chiotasso D; Coustets B; Suc A; Timsit P; Mouthon L; Mazereeuw-Hautier J
    Ann Dermatol Venereol; 2016 Dec; 143(12):836-840. PubMed ID: 27496274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose UVA1 radiation therapy for localized scleroderma.
    Stege H; Berneburg M; Humke S; Klammer M; Grewe M; Grether-Beck S; Boedeker R; Diepgen T; Dierks K; Goerz G; Ruzicka T; Krutmann J
    J Am Acad Dermatol; 1997 Jun; 36(6 Pt 1):938-44. PubMed ID: 9204059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose UVA phototherapy for treatment of localized scleroderma.
    Kerscher M; Volkenandt M; Gruss C; Reuther T; von Kobyletzki G; Freitag M; Dirschka T; Altmeyer P
    J Am Acad Dermatol; 1998 Jan; 38(1):21-6. PubMed ID: 9448200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrence of morphea after successful ultraviolet A1 phototherapy: A cohort study.
    Vasquez R; Jabbar A; Khan F; Buethe D; Ahn C; Jacobe H
    J Am Acad Dermatol; 2014 Mar; 70(3):481-8. PubMed ID: 24365168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of medium-dose ultraviolet A1 phototherapy in localized scleroderma.
    Su O; Onsun N; Onay HK; Erdemoglu Y; Ozkaya DB; Cebeci F; Somay A
    Int J Dermatol; 2011 Aug; 50(8):1006-13. PubMed ID: 21781079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case Report: Pansclerotic Morphea-Clinical Features, Differential Diagnoses and Modern Treatment Concepts.
    Ventéjou S; Schwieger-Briel A; Nicolai R; Christen-Zaech S; Schnider C; Hofer M; Bogiatzi S; Hohl D; De Benedetti F; Morren MA
    Front Immunol; 2021; 12():656407. PubMed ID: 33767715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultraviolet A1 phototherapy decreases inhibitory SMAD7 gene expression in localized scleroderma.
    Kreuter A; Hyun J; Skrygan M; Sommer A; Tomi NS; Breuckmann F; Altmeyer P; Gambichler T
    Arch Dermatol Res; 2006 Nov; 298(6):265-72. PubMed ID: 17009056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined treatment with calcipotriol ointment and low-dose ultraviolet A1 phototherapy in childhood morphea.
    Kreuter A; Gambichler T; Avermaete A; Jansen T; Hoffmann M; Hoffmann K; Altmeyer P; von Kobyletzki G; Bacharach-Buhles M
    Pediatr Dermatol; 2001; 18(3):241-5. PubMed ID: 11438008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological effects of a new ultraviolet A
    Arndt S; Lissner C; Unger P; Bäumler W; Berneburg M; Karrer S
    Exp Dermatol; 2020 Dec; 29(12):1199-1208. PubMed ID: 32592187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disabling pansclerotic morphea: clinical presentation in two adults.
    Maragh SH; Davis MD; Bruce AJ; Nelson AM
    J Am Acad Dermatol; 2005 Aug; 53(2 Suppl 1):S115-9. PubMed ID: 16021158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Generalized circumscribed scleroderma with blisters].
    Wagner G; Meyer V; Sachse MM
    Hautarzt; 2017 Jul; 68(7):566-570. PubMed ID: 28303284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.